About Our Team

Driving Growth in Medical Affairs, HEOR, RWE, and Market Access

At Franklin Pharmaceutical Consulting (FPC), we understand the importance of demonstrating and communicating the value of a product or medication, and we are there to personally assist you through every step of the process. Our team has decades of experience across therapeutic areas, including rare diseases and oncology. Leveraging the advanced expertise of our team, we offer a senior-level approach to every project.  FPC clients include multiple Fortune 200 pharmaceutical and biopharmaceutical companies.

FPC was founded in 2010 by Meg Franklin, PharmD, PhD. Offering customized solutions for every client, we provide quality consulting services for pharmaceutical companies and related stakeholders.

Examples of our commonly requested services include:

• value messaging and strategy
• observational study design and analysis/interpretation
• medical communications (abstracts, manuscripts, posters, dossiers, and slide decks)
• project oversight
• economic modeling assistance and interpretation

At the convergence of long-term trends driving growth in medical affairs, HEOR, RWE, and market access:

• Conventional and transactional commercial interactions are decreasing, and the prescriber-facing model is becoming more medicalized and engagement non-linear
• Compliance and increased regulatory controls are driving increased separation of medical and commercial functions
• Adaptive licensing, rise of patient centered and long-term outcomes are requiring sustained medical input, strategic long-term and integrated planning, and new approaches
• Greater requirements for post-marketing evidence – across safety/risk management, patient populations, and value to patients and payers
• Increased hurdles for market access requiring real world and increasingly localized evidence